DLBCL patients at academic centers had significantly better survivalMay 11, 2020DLBCLLymphoma & Plasma Cell Disorders
REGN1979 shows good activity in pretreated aggressive B-NHLJanuary 15, 2020Follicular LymphomaDLBCLLymphoma & Plasma Cell Disorders
NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomasJanuary 14, 2020PediatricsDLBCLLymphoma & Plasma Cell Disorders
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Lymphoma & Plasma Cell DisordersDLBCLFollicular LymphomaImmuno-oncologyImmunotherapy
Adding polatuzumab extends survival in relapsed/refractory DLBCLNovember 16, 2019DLBCLLymphoma & Plasma Cell Disorders
Armored CAR T cells elicit responses in NHL patientsNovember 12, 2019DLBCLLymphoma & Plasma Cell DisordersFollicular LymphomaImmunotherapyImmuno-oncology
CAR T-cell therapy found safe, effective for HIV-associated lymphomaSeptember 20, 2019Lymphoma & Plasma Cell DisordersImmunotherapyDLBCL
Study confirms prognostic impact of MYC partner gene in DLBCLSeptember 17, 2019DLBCLLymphoma & Plasma Cell Disorders
Chemo-free combo gets high response rate in relapsed or refractory DLBCLJuly 23, 2019DLBCLLymphoma & Plasma Cell Disorders
CAR T-cell therapy less effective in transformed follicular lymphomaJuly 22, 2019Follicular LymphomaLymphoma & Plasma Cell DisordersDLBCL
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCLJuly 18, 2019DLBCLLymphoma & Plasma Cell Disorders
On second thought, lenalidomide does improve DLBCL outcomesJuly 15, 2019DLBCLLymphoma & Plasma Cell Disorders
CNS-directed therapy appears more effective for synDLBCLJuly 9, 2019Lymphoma & Plasma Cell DisordersDLBCL
